TerminatedPhase 4

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

Stopped: lack of funding

United States3 participantsStarted 2009-07-06

Plain-language summary

This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.

Who can participate

Age range19 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Recipient of a kidney transplant at UNMC, including cadaveric or living donor transplant. Exclusion Criteria: * A previous diagnosis of diabetes or previous criteria for diabetes, according to the American Diabetes Association, not previously recognized as diabetes. * Simultaneous transplant of another solid organ, such liver or heart. * Patient unable to take oral medication. * Patient unable to give informed consent. * Hypersensitivity to sitagliptin.

What they're measuring

Fasting Blood Glucose

Timeframe: 1 year

Trial details

NCT IDNCT00936663

SponsorUniversity of Nebraska

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-05-01

Results submitted2018-02-08

View on ClinicalTrials.gov More Type 2 Diabetes trials